Amitriptyline in Dogs and Cats: Extralabel Behavioral Pharmacology, Dosing, and Evidence

Bottom line

Amitriptyline is a first-generation tricyclic antidepressant (TCA) used extralabel in dogs and cats: there is no FDA-approved veterinary formulation, so every use is off-label of the human product. It is a defensible adjunct to behavior modification for canine and feline anxiety and for feline urine marking, but it is not a monotherapy and it is not first-line for feline idiopathic cystitis, where the controlled evidence is mixed-to-negative and multimodal environmental modification (MEMO) remains the foundation [4][5][7]. The load-bearing safety point: amitriptyline is serotonergic, so combining it with SSRIs, MAO inhibitors, tramadol, or other serotonergic drugs carries serotonin syndrome risk [6][2]. Counsel owners that behavioral effect takes weeks, not days, and taper on discontinuation rather than stopping abruptly [1][2].

Drug facts

• Class: tricyclic antidepressant (TCA).
• Mechanism: inhibits presynaptic reuptake of serotonin and norepinephrine; it is also antihistaminic, anticholinergic (antimuscarinic), and alpha-1-adrenergic-blocking, and that ancillary receptor activity drives most of the adverse-effect profile [2][1].
• Regulatory status: human drug, NOT FDA-approved for any animal species. All veterinary use is extralabel.
• Practice indications (all extralabel): in dogs, separation anxiety, anxiety-related aggression, and submissive/excitement urination; in cats, anxiety, urine marking/inappropriate elimination, hypervocalization, and overgrooming/psychogenic alopecia [1]. Also used as a long-term adjunct in severe, refractory feline idiopathic (interstitial) cystitis / Pandora syndrome, with the caveats below [3][4][5].
• Onset: not immediate. The Merck Veterinary Manual cites 7 to 30 days [1]; Crowell-Davis describes onset over several days to several weeks and warns the drug should not be dosed on an as-needed basis [2]. Plan for a 2-to-4-week behavioral trial before judging response.

Efficacy: what the evidence actually supports

The behavioral indications rest largely on clinical experience and small case series rather than large randomized trials, and the strongest controlled evidence, which is in feline idiopathic cystitis (FIC), is largely negative for short-term use.

For canine and feline anxiety and feline urine marking, amitriptyline is used as an adjunct to behavior modification [1]; the supporting data are experiential, and for marking or generalized anxiety an SSRI (fluoxetine) or the sibling TCA clomipramine often carries better-characterized evidence.

For FIC the literature must be read from both sides:

• Chew et al. (1998): an open-label study of 15 cats with severe recurrent idiopathic cystitis given amitriptyline 10 mg per cat PO q24h in the evening. Clinical signs decreased in 9 of 15 cats over 12 months, but weight gain, decreased grooming, somnolence, and transient cystic calculi were observed [3].
• Kruger et al. (2003): a randomized, placebo-controlled trial of short-term amitriptyline (5 mg per cat per day for 7 days) for acute nonobstructive idiopathic lower urinary tract disease found no benefit; clinical signs recurred significantly faster and more frequently in amitriptyline-treated cats than in controls [4].
• Kraijer et al. (2003): a controlled study of a 7-day course of amitriptyline 10 mg once daily likewise found it not effective for idiopathic FLUTD [5].

Neutral synthesis: short-course amitriptyline is not supported for acute FIC and may worsen recurrence [4][5]; any role is confined to severe, chronic, refractory cases as a long-term adjunct after other measures fail [3]. Multimodal environmental modification (MEMO) reduces recurrent lower-urinary-tract signs and remains first-line for FIC [7].

Adverse effects

Sedation and anticholinergic effects dominate the clinical picture.

• Sedation/somnolence, often most pronounced early and frequently transient [1][2][3].
• Anticholinergic effects: urine retention, constipation, decreased salivation and lacrimation, and mydriasis [1][2].
• Cardiac: arrhythmias including tachycardia; overt cardiotoxicity is a higher-exposure phenomenon (Crowell-Davis reports experimental cardiotoxicity at roughly 15 to 80 mg/kg) [1][2].
• Weight gain and increased appetite [1][2][3].
• Decreased grooming/coat quality and transient cystic calculi were documented in the FIC cohort [3].

Contraindications, cautions, and interactions

• Serotonin syndrome (the load-bearing interaction): amitriptyline is serotonergic. Stacking it with SSRIs (fluoxetine, sertraline, paroxetine), MAO inhibitors (selegiline, and amitraz-containing products), tramadol, or other serotonergic agents can precipitate serotonin syndrome; Clinician's Brief lists these among drugs that should be avoided in combination [6], and Crowell-Davis states that TCAs should never be given with MAOIs [2]. Watch for agitation, tremors, hyperthermia, and arrhythmias.
• Cardiac disease: avoid or use cautiously given the arrhythmogenic potential of TCAs [2][1].
• Anticholinergic burden: use caution where urinary retention or glaucoma would be worsened [1][2]. Confirm hepatic-impairment dosing in Plumb's before dispensing.
• Do not discontinue abruptly: patients maintained on daily amitriptyline for several weeks should be withdrawn gradually [2].

Dosing and administration

All dosing is extralabel; start low and titrate. The figures below are transcribed from Crowell-Davis (Veterinary Psychopharmacology, tricyclic antidepressants):

• Dog: 1-6 mg/kg PO q12h [2].
• Cat: 0.5-2.0 mg/kg PO q12-24h [2].
• Always begin at the low end of the range and titrate up if response is inadequate [2]; behavioral protocols typically start near the bottom of these ranges.
• Feline idiopathic cystitis (refractory cases only): Chew et al. used 10 mg per cat PO q24h in the evening [3].

Confirm the exact per-patient dose, and any indication- or species-specific figure, against Plumb's Veterinary Drug Handbook before dispensing, and taper on discontinuation [2].

Monitoring

• Baseline physical exam with CBC and biochemistry; consider ECG or cardiac evaluation in geriatric or cardiac-suspect patients given the arrhythmogenic potential [1][2].
• Track behavioral response over weeks rather than days, and continue through the titration window before judging efficacy [1][2].
• Re-check for anticholinergic effects (urine retention, constipation) and for weight gain at follow-up [1][2].

Alternatives

• Fluoxetine, an SSRI, is a common first-line choice for canine anxiety and is frequently preferred for feline marking; see the fluoxetine hub.
• Sertraline is an alternative SSRI for anxiety in both species; see the sertraline hub.
• Clomipramine is the other veterinary TCA and, unlike amitriptyline, has an FDA-approved canine formulation for separation anxiety; see the clomipramine hub.
• Buspirone is an azapirone anxiolytic useful for feline urine marking and situational anxiety; see the buspirone hub.
• Gabapentin is worth considering for situational feline anxiety and fear-based handling.

When switching between serotonergic agents, account for serotonin syndrome risk and washout as appropriate [6].

Frequently Asked Questions

What is the amitriptyline dose for dogs and cats? All use is extralabel. Crowell-Davis (Veterinary Psychopharmacology) lists 1-6 mg/kg PO q12h for dogs and 0.5-2.0 mg/kg PO q12-24h for cats, starting at the low end and titrating up. For severe recurrent feline idiopathic cystitis, Chew et al. (JAVMA 1998) used 10 mg per cat PO q24h. Confirm the per-patient dose in Plumb's Veterinary Drug Handbook before dispensing.

Is amitriptyline FDA-approved for dogs or cats? No. Amitriptyline is a human tricyclic antidepressant with no FDA-approved veterinary formulation, so every use in dogs and cats is extralabel. Its sibling TCA clomipramine, by contrast, does have an FDA-approved canine product for separation anxiety.

Does amitriptyline work for feline idiopathic cystitis (FIC)? The controlled evidence is mixed-to-negative for short courses. Two controlled studies, Kruger et al. (JAVMA 2003) and Kraijer et al. (Journal of Feline Medicine and Surgery 2003), found no benefit from roughly 7-day amitriptyline, and Kruger reported faster and more frequent recurrence in treated cats. An older open-label series, Chew et al. (JAVMA 1998), suggested benefit only in severe, refractory, chronic cases. Multimodal environmental modification (MEMO; Buffington et al., Journal of Feline Medicine and Surgery 2006) remains first-line.

Can amitriptyline be combined with fluoxetine or another SSRI? Only with serotonin syndrome risk explicitly in mind. Clinician's Brief (Almgren and Lee) lists SSRIs, MAO inhibitors (selegiline, amitraz), and tramadol among serotonergic drugs that should be avoided in combination, and Crowell-Davis states TCAs should never be given with MAOIs. If serotonergic drugs are layered, monitor for agitation, tremors, hyperthermia, and arrhythmias.

How long does amitriptyline take to work? Weeks, not days. The Merck Veterinary Manual cites 7 to 30 days, and Crowell-Davis describes onset over several days to several weeks and cautions that amitriptyline is not an as-needed drug. Plan for a 2-to-4-week trial and counsel owners to continue dosing through the titration window.

What are the main adverse effects of amitriptyline? Sedation and anticholinergic effects predominate: urine retention, constipation, decreased salivation and lacrimation, and mydriasis (Merck Veterinary Manual; Crowell-Davis), plus weight gain and, at higher or overdose exposures, cardiac arrhythmias. The feline idiopathic cystitis cohort in Chew et al. also showed decreased grooming and transient cystic calculi.

Do I need to taper amitriptyline when stopping it? Yes. Crowell-Davis advises that patients maintained on daily amitriptyline for several weeks be withdrawn gradually rather than stopped abruptly.

Which patients should not receive amitriptyline? Use caution or avoid it in patients with cardiac disease, given its arrhythmogenic potential (Crowell-Davis; Merck Veterinary Manual), in patients already on serotonergic drugs because of serotonin syndrome risk (Clinician's Brief), and where anticholinergic effects would be harmful, such as urinary retention or glaucoma. Confirm hepatic-impairment dosing in Plumb's.